INTELLIGENT BIO SOLUTIONS INC. — fact timeline

INTELLIGENT BIO SOLUTIONS INC. entered into Securities Purchase Agreement with two healthcare focused institutional investors valued at approximately $10.0 million (effective 2025-12-31).

“On December 31, 2025, Intelligent Bio Solutions Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with two healthcare focused institutional investors for the sale by the Company of (i) 2,298,850 shares (the “Shares”) of the Company’s common stock (or Series L Pre-funded warrants in lieu thereof (the “Pre-Funded Warrants”)), par value $0.01 per share (the “Common Stock”), (ii) Series K-1 warrants to purchase up to an aggregate of 2,298,850 shares of Common Stock (the “Series K-1 Warrants”), and (iii) Series K-2 warrants to purchase up to an aggregate of 2,298,850 shares of Common Stock (the “Series K-2 Warrants” and, collectively with the Series K-1 Warrants and Pre-Funded Warrants, the “Warrants”), in a private placement offering (the “Offering”).”

INTELLIGENT BIO SOLUTIONS INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“December 15, 2025, Intelligent Bio Solutions Inc. (the “Company”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) notifying the Company that because the closing bid price for the Company’s common stock was below $1.00 per share for the last 30 consecutive business days, the Company did not meet the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). The deficiency letter does not result in the immediate delisting of the Company’s common”

INTELLIGENT BIO SOLUTIONS INC.: Approved amendment to Certificate of Incorporation to effect a 1-for-10 reverse stock split (effective 2025-12-15).

“At the annual meeting of stockholders of Intelligent Bio Solutions Inc. (the “Company”) held on October 16, 2025, the Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Amendment”) to effect a reverse stock split at a ratio of not less than 1-for-2 and not more than 1-for-10 at any time within 12 months following the date of such stockholder approval, with the exact ratio to be set within this range by the Company’s Board of Directors (the “Board”) at its sole discretion without further approval or authorization of the Company’s stockholders.”

Nicola Fraser was appointed as Director at INTELLIGENT BIO SOLUTIONS INC..

“On June 7, 2024, upon recommendation of the Nominating and Corporate Governance Committee, the Board appointed Nicola Fraser to the Board to fill the vacancy created by Mr. Tower’s resignation.”

Christopher Towers resigned as Director at INTELLIGENT BIO SOLUTIONS INC..

“On June 6, 2024, Christopher Towers resigned from the Board of Directors (the “Board”) of Intelligent Bio Solutions Inc. (the “Company”), effective June 7, 2024.”

INTELLIGENT BIO SOLUTIONS INC. reported nine months ended March 31, 2024 results: revenue $2.38 million, net income $7.37 million.

“Total revenue for the nine months ended March 2024 was $2.38 million, an increase of 193% compared to the same period the year prior.”

INTELLIGENT BIO SOLUTIONS INC. reported fiscal third quarter ended March 31, 2024 results: revenue $0.82 million, net income $2.98 million.

“Total revenues for the fiscal third quarter were $0.82 million, an increase of 80% compared to the same period the year prior.”

INTELLIGENT BIO SOLUTIONS INC. reported the fiscal third quarter and nine months ended March 31, 2024 results: revenue $0.82 million.

“today announced preliminary unaudited revenue results for the fiscal third quarter and nine months ended March 31, 2024. The Company expects approximate unaudited revenue of $0.82 million for the three months ended March 31, 2024, representing an increase of 80% compared to the same period the prior year, and approximate unaudited revenue of $2.38 million for the”

INTELLIGENT BIO SOLUTIONS INC. entered into Securities Purchase Agreement with several institutional and accredited investors (effective 2024-03-08).

“On March 8, 2024, Intelligent Bio Solutions Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with several institutional and accredited investors”

INTELLIGENT BIO SOLUTIONS INC. entered into Consulting Agreement with C2C Advisors Inc. valued at $25,000 per month (effective 2024-02-29).

“On February 29, 2024, Intelligent Bio Solutions Inc. (the “Company”) entered into a Consulting Agreement (the “C2C Agreement”) with C2C Advisors Inc. (“C2C”) pursuant to which C2C will provide certain advisory and investor relations services to the Company.”